 |
Companies | Products |
|
|
Products | |
Diseases | |
Trials |  |
News |  |
| «12...3456789101112131415 |
- || Darzalex IV (daratumumab) / J&J
P1 data, Preclinical, Journal: CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging. (Pubmed Central) - Aug 1, 2020
Purpose To demonstrate preclinical and first-in-human application of an antibody composed of the native daratumumab labeled with the positron-emitting radionuclide zirconium 89 (Zr) through the chelator deferoxamine (DFO), or Zr-DFO-daratumumab, for immunologic PET imaging of multiple myeloma. Conclusion These data demonstrate successful CD38-targeted immunologic PET imaging of multiple myeloma in a murine model and in humans.
- || Review, Journal: The Anti-CD38 Antibody Therapy in Multiple Myeloma. (Pubmed Central) - Jul 31, 2020
In addition, drugs with a different mechanism of action, such as the histone deacetylase inhibitor and the monoclonal antibodies (MoAb) targeting SLAMF7 or CD38, are a part of the anti-myeloma armamentarium and are very important for heavily pretreated or double refractory to a PI and IMiD patients. In this paper, we focus on the efficacy as well as toxicities of CD38 antibodies used both as a single agent and in combination as multiple myeloma treatment.
- Xpovio (selinexor) / Ono Pharma, Karyopharm, Antengene
[VIRTUAL] Matching-adjusted indirect comparisons (MAIC) of safety between single-agent belantamab mafodotin versus selinexor plus dexamethasone in relapsed/refractory multiple myeloma (RRMM) (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1717;
P2, P2b
Drug linker technology licensed from Seattle Genetics; Monoclonal antibody produced using POTELLIGENT Technology licensed from BioWa. Clinical trial identification: DREAMM-2: NCT03525678; STORM: NCT02336815.
- [VIRTUAL] DEPTH OF RESPONSE TO DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IMPROVES OVER TIME IN PATIENTS WITH TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: GRIFFIN STUDY UPDATE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_5226;
P2
The overall safety profile of D-RVd is consistent with previous reports of DARA plus SoC. Stem cell mobilization and ASCT are feasible with D-RVd, without a significant effect on hematopoietic reconstitution.
- [VIRTUAL] DEPTH OF RESPONSE TO DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IMPROVES OVER TIME IN PATIENTS WITH TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: GRIFFIN STUDY UPDATE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_5225;
P2
The overall safety profile of D-RVd is consistent with previous reports of DARA plus SoC. Stem cell mobilization and ASCT are feasible with D-RVd, without a significant effect on hematopoietic reconstitution.
- [VIRTUAL] DEPTH OF RESPONSE TO DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IMPROVES OVER TIME IN PATIENTS WITH TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: GRIFFIN STUDY UPDATE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_5224;
P2
The overall safety profile of D-RVd is consistent with previous reports of DARA plus SoC. Stem cell mobilization and ASCT are feasible with D-RVd, without a significant effect on hematopoietic reconstitution.
- [VIRTUAL] ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE MYELOMA: SINGLE CENTER EXPERIENCE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4387;
Our results are similar to published on literature. In our patients, the morbidity and mortality was acceptable with the limitation of a high rate of cGVHD.
- [VIRTUAL] ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE MYELOMA: SINGLE CENTER EXPERIENCE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4386;
Our results are similar to published on literature. In our patients, the morbidity and mortality was acceptable with the limitation of a high rate of cGVHD.
- [VIRTUAL] ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE MYELOMA: SINGLE CENTER EXPERIENCE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4385;
Our results are similar to published on literature. In our patients, the morbidity and mortality was acceptable with the limitation of a high rate of cGVHD.
- || Blenrep (belantamab mafodotin-blmf) / GSK
Trial completion date, Immunomodulating: DREAMM 2: A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody (clinicaltrials.gov) - Apr 27, 2020
P2, N=221, Active, not recruiting, Sponsor: GlaxoSmithKline
In our patients, the morbidity and mortality was acceptable with the limitation of a high rate of cGVHD. Trial completion date: Jun 2020 --> Nov 2020
- ||| STI-6129 / Sorrento
New P1 trial: Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis (clinicaltrials.gov) - Mar 19, 2020
P1, N=60, Not yet recruiting, Sponsor: Sorrento Therapeutics, Inc.
- [VIRTUAL] DEPTH OF RESPONSE TO DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IMPROVES OVER TIME IN PATIENTS WITH TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: GRIFFIN STUDY UPDATE (ePoster Area) - Feb 8, 2020 - Abstract #EBMT2020EBMT_2091;
P2
The overall safety profile of D-RVd is consistent with previous reports of DARA plus SoC. Stem cell mobilization and ASCT are feasible with D-RVd, without a significant effect on hematopoietic reconstitution.
- [VIRTUAL] ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE MYELOMA: SINGLE CENTER EXPERIENCE (ePoster Area) - Feb 8, 2020 - Abstract #EBMT2020EBMT_1654;
Our results are similar to published on literature. In our patients, the morbidity and mortality was acceptable with the limitation of a high rate of cGVHD.
- | Blenrep (belantamab mafodotin-blmf) / GSK
Enrollment change, Immunomodulating: DREAMM 2: A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody (clinicaltrials.gov) - Jul 8, 2019
P2, N=223, Active, not recruiting, Sponsor: GlaxoSmithKline
In our patients, the morbidity and mortality was acceptable with the limitation of a high rate of cGVHD. N=155 --> 223
- || Blenrep (belantamab mafodotin-blmf) / GSK
Enrollment closed, Immunomodulating: DREAMM 2: A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody (clinicaltrials.gov) - Jun 12, 2019
P2, N=155, Active, not recruiting, Sponsor: GlaxoSmithKline
N=155 --> 223 Recruiting --> Active, not recruiting
- ||| Blenrep (belantamab mafodotin-blmf) / GSK
Enrollment open, Immunomodulating: DREAMM 2: A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody (clinicaltrials.gov) - Jul 8, 2018
P2, N=155, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| Blenrep (belantamab mafodotin-blmf) / GSK
New P2 trial, Immunomodulating: DREAMM 2: A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody (clinicaltrials.gov) - May 18, 2018
P2, N=150, Not yet recruiting, Sponsor: GlaxoSmithKline